Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Dec;37(4):396-9.

An isolated limb infusion technique: a guide for the perfusionist

Patricia McDermott  1 , D Scott Lawson, Richard Walczak Jr, Douglas Tyler, Ian R Shearer
Affiliations

An isolated limb infusion technique: a guide for the perfusionist

Patricia McDermott et al. J Extra Corpor Technol. 2005 Dec.

Abstract

Isolated limb perfusion with the administration of cytotoxic drugs has been successfully used to treat melanomas of the extremity since it was first introduced in 1958. The use of hyperthermia (40 degrees C) combined with chemotherapy agents, primarily melphalan, has resulted in greater cytotoxicity in laboratory studies, which led to the application of hyperthermia in clinical studies during the 1960s. The effectiveness of this regional technique and the absence of any good systemic therapy made hyperthermic-isolated limb perfusion (HILP) the main treatment for patients with regionally advanced melanoma. HILP involves open surgical dissection and cannulation of the peripheral vessels and is associated with moderate morbidity rates. Blood transfusions, systemic drug leak, infection, and damage to the blood vessels and nerves are all potential hazards associated with this technique. Recently, however, there has been increased interest in an alternative technique termed isolated limb infusion (ILI), which was first reported in 1994 from the Sydney Melanoma Unit in Australia. Based on a few single institution experiences, it was found that there are fewer morbidities associated with HILP than with ILI but no compromise in patient outcomes. ILI is a less invasive procedure involving the use of angiographically placed catheters inserted percutaneously through the femoral vessels that does not require blood donor exposure or use of a heart lung machine. Preliminary data suggest that the resultant local hypoxia and acidosis induced by this procedure potentiates the cytotoxic effects of melphalan. Response rates comparing ILI to HILP seem similar, and both are markedly better than systemic chemotherapy. ILI may be a more desirable option because morbidity is greatly reduced and outcomes appear similar. There is a potential role for the perfusionist in the application of ILI, an evolving area of cancer therapy.

PubMed Disclaimer

Conflict of interest statement

The senior author has stated that authors have reported no material, financial or other relationship with any healthcare-related business or other entity whose products or services are discussed in this paper.

Figures

Figure 1.
Figure 1.
Diagram of isolated limb infusion circuit. ID, inner diameter.
See this image and copyright information in PMC

References

    1. Thompson JF, Waugh RC, Saw RM, Kam P.. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–92.
    1. Thompson JF, Kam PC, Waugh RC, Harman R.. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb per-fusion. Semin Surg Oncol. 1998;14:238–47. - PubMed
    1. Thompson JF, Lai DM, Ingvar C, Kam PC.. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994;4(Suppl 1):45–50. - PubMed
    1. Thompson JF, deWilt JF.. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol. 2001;8:564–5. - PubMed
    1. Thompson JF, Hunt JA, Shannon KF, Kam PC.. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132:903–7. - PubMed

MeSH terms

Substances

LinkOut - more resources